

Anti-KLK7 Reference Antibody (Genentech patent anti-KLK7)

Catalog # APR11338

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P49862
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	27525


Additional Information

Target/Specificity	KLK7
Expression system	CHO


Protein Information

Name	KLK7
Synonyms	PRSS6, SCCE
Function	May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at '14-Tyr- -Gln-15' and insulin B chain at '6-Leu- -Cys-7', '16-Tyr- -Leu-17', '25-Phe- -Tyr-26' and '26-Tyr- -Thr-27'. Could play a role in the activation of precursors to inflammatory cytokines.
Cellular Location	Secreted. Note=In ovarian carcinoma, secreted and also observed at the apical membrane and in cytoplasm at the invasive front
Tissue Location	Abundantly expressed in the skin and is expressed by keratinocytes in the epidermis. Also expressed in the brain, mammary gland, cerebellum, spinal cord and kidney. Lower levels in salivary glands, uterus, thymus, thyroid, placenta, trachea and testis. Up- regulated in ovarian carcinoma, especially late-stage serous carcinoma, compared with normal ovaries and benign adenomas (at protein level)


Images



anti-KLK7) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-KLK7 Reference Antibody (Genentech patent anti-KLK7) is 99.71%, determined by SEC-HPLC.



Immobilized Hu KLK7-his at 2 µg/mL can bind Genentech patent anti-KLK7, EC₅₀= 0.0212 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.